Amphastar Pharmaceuticals, Inc. announced on August 12, 2025, that it has entered into an exclusive license agreement with Nanjing Anji Biotechnology Co., Ltd. ("Anji"). This agreement covers the development, manufacturing, use, and commercialization of three proprietary peptides in the United States and Canada.
The agreement strengthens Amphastar's proprietary peptide pipeline, targeting high-value oncology and ophthalmology indications. The first product is based on Anji’s discovery of an endogenous peptide that demonstrates a novel mechanism of action, potentially suppressing the growth and metastasis of multiple poorly treated cancers.
Amphastar made an earnest money payment of $0.75 million and an upfront payment of $5.25 million to Anji. The agreement includes additional potential development milestone payments of up to $42 million and sales milestone payments of up to $225 million, with Anji potentially receiving up to $453 million in total payments over the agreement’s lifetime.
This strategic move into advanced therapeutic areas aligns with Amphastar's pivot towards high-value, innovation-led growth. The potential for a novel mechanism of action in cancer treatment represents a significant long-term opportunity, diversifying the company's product portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.